Report of Foreign Issuer (6-k)
October 19 2017 - 7:13AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Form 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of October 2017
Commission
File Number 001-37846
CELLECT
BIOTECHNOLOGY LTD.
(Translation
of registrant’s name into English)
23
Hata’as Street
Kfar
Saba, Israel 44425
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
This
Form 6-K and the first paragraph and “Forward Looking Statements” of the press release attached to this Form 6-K of
the Registrant are incorporated by reference into the registrant’s Registration Statements on Form S-8 (Registration
No. 333-214817 and 333-220015) and on Form F-3 (Registration No. 333-219614 and 333-212432).
On October 17, 2017, the Board of Directors (the “Board”) of Cellect Biotechnology Ltd. (the “Company”)
appointed Dr. Ronit Bakimer-Kleiner to serve as the Company’s Chief Development Officer commencing November 7, 2017. Dr.
Bakimer-Kleiner will replace Yaron Pereg who is stepping down as the Company’s Chief Development Officer, effective October
25, 2017.
Prior
to joining the Company, from 2008 to 2017, Dr. Bakimer-Kleiner served as General Manager of Cognate Bioservices Israel, a contract
bioservices organization focused on the regenerative medicine and cell therapy market. Prior to that from 2006 to 2008, Dr. Bakimer-Kleiner
was Laboratory Director at the International Center for Cell Therapy & Cancer at Tel Aviv Sourasky Medical Center and from
1997 to 2006 held various positions at Proneuron Biotechnologies including Director of Cell Therapy. Dr. Bakimer-Kleiner holds
a B.Sc. in Life Sciences from Tel Aviv University and a M.Sc. and Ph.D. in Immunology from Ben-Gurion University followed by 4
years post-doc at The Weizmann Institute of Science.
On
October 19, 2017, the Company issued a press release announcing the appointment of Dr. Bakimer-Kleiner. A copy of the press release
is attached hereto as Exhibit 99.1, and is incorporated herein by reference.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Cellect
Biotechnology Ltd.
|
|
|
|
Date:
October 19, 2017
|
By:
|
/s/
Eyal Leibovitz
|
|
|
Name:
Eyal Leibovitz
|
|
|
Title:
Chief Financial Officer
|
3
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Jul 2023 to Jul 2024